FDA Office of New Drugs (correction)
Executive Summary
A chart outlining the new structure of the Office of New Drugs published in the June 27 issue of "The Pink Sheet" incorrectly reported the status of the division directors in the Office of Non-Prescription Products. Curtis Rosebraugh is acting director for the Division of Non-Prescription Clinical Evaluation, and Susan Johnson is acting director for the Division of Non-Prescription Regulation Development. An accompanying story also suggested that Robert Justice is the permanent director of the Division of Drug Oncology Products; he will serve on an acting basis...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.